Analysts’ Viewpoint
Launch of new and innovative therapies for treatment of heart diseases is driving the global cardiology stem cells market. Advancements in stem cell research and surge in incidence of cardiovascular diseases are expected to propel market expansion in the next few years. Furthermore, increase in healthcare spending and rise in awareness about the benefits of early detection and treatment are expected to bolster market development in the near future.
Increase in adoption of stem cell technology in emerging economies, surge in investment in stem cell research, and rise in number of clinical trials focused on cardiac stem cell therapies offer lucrative opportunities for market players. Companies are focusing on introduction of new products with advanced technology for the treatment cardiovascular diseases.
Cardiac stem cell therapy refers to a specialized branch of regenerative medicine that focuses on using stem cells to repair and regenerate damaged heart tissue. Stem cells are undifferentiated cells that have the potential to develop into various types of cells in the body. In cardiology, stem cells can be used to replace damaged heart muscle cells, promote the growth of new blood vessels, and improve overall heart function. Cardiac stem cells can be obtained from various sources such as bone marrow, adipose tissue, and embryonic or induced pluripotent stem cells.
Several clinical trials have been conducted to evaluate the safety and efficacy of cardiovascular stem cell therapies, and results have shown promising outcomes in improving heart function and reducing symptoms in patients with heart disease.
Stem cell therapy aims to deliver the best cells to the best location at the best time for the longest possible period in order to obtain the best patient outcomes. Metrics including ejection fraction, mixed venous oxygen saturation (MVO2), objective measurements of ischemia, and mortality are used to gauge improved outcomes for doctors. Patients express their expectations of results in more ethereal words, such as cessation of chest pain, diminution of breathlessness, improvement in exercise tolerance, and extension of life. Regardless of the criteria, stem cell therapy has the potential to improve patient outcomes and is getting closer to becoming a reality.
Advances in stem cell research have led to a better understanding of stem cells and their potential applications in regenerative medicine, including cardiology stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to become pluripotent, meaning they have the ability to differentiate into any cell type in the body. This technology has the potential to overcome some of the ethical concerns associated with embryonic stem cells and allows for the creation of patient-specific stem cell lines, which can be used for personalized medicine.
CRISPR/Cas9 gene editing is a powerful gene editing tool that can be used to manipulate the genetic material of stem cells to correct disease-causing mutations or introduce beneficial traits. This technology has the potential to revolutionize the development of stem cell therapies and personalized medicine. Organoids are three-dimensional structures that mimic the complex organization and function of organs in the body. Tissue engineering involves the creation of functional tissues using stem cells and scaffolds. These technologies have the potential to revolutionize the development of personalized therapies and improve our understanding of human physiology and disease. Advances in biomaterials and microscale engineering have led to the development of new delivery methods for stem cell therapies.
The need for new and innovative therapies to treat heart disease is a major driver of the global cardiology stem cells market growth. Heart disease is a leading cause of death globally. Current treatments such as medications, surgery, and lifestyle modifications have limitations and are not effective for all patients.
Cardiology stem cell therapy offers a potential new treatment option for heart disease. This therapy involves the usage of stem cells to repair damaged heart tissue, promote angiogenesis, and improve overall heart function. Clinical trials have shown promising results with cardiology stem cell therapies, providing evidence of their safety and effectiveness in improving heart function and reducing symptoms in patients with heart disease.
The potential benefits of cardiology stem cell therapy, combined with the need for new and innovative therapies for heart disease, are driving market progress.
In terms of type of cell, the adult stem cells segment dominated the global cardiology stem cells market in 2022. Adult stem cells can be easily harvested from a patient's own body, eliminating the need for a donor and reducing the risk of rejection. Moreover, these have a lower risk of forming tumors compared to embryonic stem cells. This reduces the risk of complications associated with cell-based therapies.
Based on application, the global cardiology stem cells market has been segregated into heart failure, myocardial infarction, critical limb ischemia, and others. The heart failure segment accounted for major share of the global market in 2022. Heart failure is a medical condition that occurs when the heart is unable to pump enough blood to meet the body's needs. This could happen when the heart becomes weak or damaged, and can lead to various symptoms, including shortness of breath, fatigue, swelling in the legs, and difficulty exercising. Cardiology stem cells to promote the regeneration and repair of damaged heart tissue.
Based on end-user, the global cardiology stem cells market has been divided into pharmaceutical and biotechnology companies, hospitals & cell banks, and academic & research institutes. The hospitals segment accounted for the largest share of the global market in 2022. Large number of heart patients prefer to have stem cell therapy at hospitals.
North America accounted for major share of the global market in 2021. The market in the region is likely to expand at a high CAGR from 2022 to 2031. The region has a number of prominent stem cell research centers and institutes, as well as companies that are working on developing stem cell-based therapies.
As per cardiology stem cells market analysis, Asia Pacific dominated the global industry in 2022. The market in the region is likely to grow at a rapid pace from 2023 to 2031. Asia Pacific is a major market for stem cell research and therapy, with several countries investing in research & development of stem cell therapies. Japan, South Korea, China, and Singapore are some of the countries in Asia Pacific with significant progress in stem cell research and development. Japan, for instance, has a well-established regulatory framework for stem cell research, and several clinical trials are currently underway to test the safety and efficacy of stem cell therapies for a range of diseases.
The global cardiology stem cells market is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and merger & acquisition are the key strategies adopted by the key players. Leading players in the global market are Astellas Pharma Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited, Cytori Therapeutics, Inc., Bio Cardia, Inc., and Lisata Therapeutics.
Each of these players has been profiled in the cardiology stem cells market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 2.6 Bn |
|
Forecast (Value) in 2031 |
US$ 5.1 Bn |
|
Growth Rate (CAGR) |
7.4% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 2.6 Bn in 2022
It is projected to reach more than US$ 5.1 Bn by 2031
The CAGR is anticipated to be 7.4% from 2023 to 2031.
Advancements in stem cell research and new & innovative therapies to treat heart diseases are driving the global cardiology stem cells market
North America is expected to account for the largest share of the global market during the forecast period.
Astellas Pharma, Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited, Cytori Therapeutics, Inc., Bio Cardia, Inc., and Lisata Therapeutics are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiology Stem Cells Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Pipeline Analysis
5.4. Disease Prevalence & Incidence Rate globally with key countries
6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Cell, 2017-2031
6.3.1. Embryonic Stem Cells
6.3.2. Adult Stem Cells
6.3.3. Induced Pluripotent Stem Cells
6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
6.4. Market Attractiveness Analysis, by Type of Cell
7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Heart Failure
7.3.2. Myocardial Infarction
7.3.3. Critical Limb Ischemia
7.3.4. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source, 2017-2031
8.3.1. Autologous
8.3.2. Allogenic
8.4. Market Attractiveness Analysis, by Source
9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Hospitals & Cell Banks
9.3.3. Academic & Research Institutes
9.4. Market Attractiveness Analysis, by End-user
10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Cardiology Stem Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Cell, 2017-2031
11.2.1. Embryonic Stem Cells
11.2.2. Adult Stem Cells
11.2.3. Induced Pluripotent Stem Cells
11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Heart Failure
11.3.2. Myocardial Infarction
11.3.3. Critical Limb Ischemia
11.3.4. Others
11.4. Market Value Forecast, by Source, 2017-2031
11.4.1. Autologous
11.4.2. Allogenic
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Pharmaceutical & Biotechnology Companies
11.5.2. Hospitals & Cell Banks
11.5.3. Academic & Research Institutes
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type of Cell
11.7.2. By Application
11.7.3. By Source
11.7.4. By End-user
11.7.5. By Country
12. Europe Cardiology Stem Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Cell, 2017-2031
12.2.1. Embryonic Stem Cells
12.2.2. Adult Stem Cells
12.2.3. Induced Pluripotent Stem Cells
12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Heart Failure
12.3.2. Myocardial Infarction
12.3.3. Critical Limb Ischemia
12.3.4. Others
12.4. Market Value Forecast, by Source, 2017-2031
12.4.1. Autologous
12.4.2. Allogenic
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Pharmaceutical & Biotechnology Companies
12.5.2. Hospitals & Cell Banks
12.5.3. Academic & Research Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type of Cell
12.7.2. By Application
12.7.3. By Source
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Cell, 2017-2031
13.2.1. Embryonic Stem Cells
13.2.2. Adult Stem Cells
13.2.3. Induced Pluripotent Stem Cells
13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Heart Failure
13.3.2. Myocardial Infarction
13.3.3. Critical Limb Ischemia
13.3.4. Others
13.4. Market Value Forecast, by Source, 2017-2031
13.4.1. Autologous
13.4.2. Allogenic
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Pharmaceutical & Biotechnology Companies
13.5.2. Hospitals & Cell Banks
13.5.3. Academic & Research Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type of Cell
13.7.2. By Application
13.7.3. By Source
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Cardiology Stem Cells Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Cell, 2017-2031
14.2.1. Embryonic Stem Cells
14.2.2. Adult Stem Cells
14.2.3. Induced Pluripotent Stem Cells
14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Heart Failure
14.3.2. Myocardial Infarction
14.3.3. Critical Limb Ischemia
14.3.4. Others
14.4. Market Value Forecast, by Source, 2017-2031
14.4.1. Autologous
14.4.2. Allogenic
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Pharmaceutical & Biotechnology Companies
14.5.2. Hospitals & Cell Banks
14.5.3. Academic & Research Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type of Cell
14.7.2. By Application
14.7.3. By Source
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Cell, 2017-2031
15.2.1. Embryonic Stem Cells
15.2.2. Adult Stem Cells
15.2.3. Induced Pluripotent Stem Cells
15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Heart Failure
15.3.2. Myocardial Infarction
15.3.3. Critical Limb Ischemia
15.3.4. Others
15.4. Market Value Forecast, by Source, 2017-2031
15.4.1. Autologous
15.4.2. Allogenic
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Pharmaceutical & Biotechnology Companies
15.5.2. Hospitals & Cell Banks
15.5.3. Academic & Research Institutes
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type of Cell
15.7.2. By Application
15.7.3. By Source
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2022)
16.3. Company Profiles
16.3.1. Astellas Pharma, Inc.
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. STEMCELL Technologies
16.3.2.1. Company Overview
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Cellular Engineering Technologies
16.3.3.1. Company Overview
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. BioTimes, Inc.
16.3.4.1. Company Overview
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Takara Bio, Inc.
16.3.5.1. Company Overview
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. U.S. Stem Cell, Inc.
16.3.6.1. Company Overview
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. BrainStorm Cell Limited
16.3.7.1. Company Overview
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Cytori Therapeutics, Inc.
16.3.8.1. Company Overview
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Bio Cardia, Inc.
16.3.9.1. Company Overview
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
List of Tables
Table 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031
Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031
Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031
Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031
Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 02: Global Cardiology Stem Cells Market Value Share, by Type of Cell, 2022
Figure 03: Global Cardiology Stem Cells Market Value Share, by Application, 2022
Figure 04: Global Cardiology Stem Cells Market Value Share, by Source, 2022
Figure 05: Global Cardiology Stem Cells Market Value Share, by End-user, 2022
Figure 06 Global Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 07: Global Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 08: Global Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 09: Global Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 10: Global Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 11: Global Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 12: Global Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031
Figure 13: Global Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 14: Global Cardiology Stem Cells Market Value Share Analysis, by Region, 2022 and 2031
Figure 15: Global Cardiology Stem Cells Market Attractiveness Analysis, by Region, 2023-2031
Figure 16: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 17: North America Cardiology Stem Cells Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Cardiology Stem Cells Market Attractiveness Analysis, by Country, 2023-2031
Figure 19: North America Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 20: North America Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 21: North America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 22: North America Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 23: North America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 24: North America Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 25: North America Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 26: North America Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 27: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 28: Europe Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 29: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Europe Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 31: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 32: Europe Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 34: Europe Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 35: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 36: Europe Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: Europe Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 38: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 39: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 40: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 41: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 42: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 43: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 44: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 45: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 46: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 47: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031
Figure 48: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 49: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 50: Latin America Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 51: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 52: Latin America Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 53: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 54: Latin America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 56: Latin America Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 57: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 58: Latin America Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031
Figure 59: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 60: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031
Figure 61: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 62: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 63: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031
Figure 64: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031
Figure 65: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031
Figure 66: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031
Figure 67: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031
Figure 68: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031
Figure 69: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031
Figure 70: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031
Figure 71: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cardiology Stem Cells Market
